RUA Life Sciences plc (AIM:RUA)

RUA Life Sciences Balance Sheet

Financials in millions GBP. Fiscal year is October - September.

Assets

Fiscal Year	TTM	FY 2025	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	2.37	3.25	3.57	3.93	1.48	2.96
Cash & Short-Term Investments	2.37	3.25	3.57	3.93	1.48	2.96
Cash Growth	-27.23%	-8.89%	-9.26%	164.89%	-49.92%	-52.92%
Accounts Receivable	0.96	0.73	1.09	0.3	0.18	0.22
Other Receivables	0.49	0.23	-	0.42	0.25	0.56
Receivables	1.45	0.96	1.09	0.72	0.42	0.78
Inventory	0.96	0.89	0.75	0.11	0.08	0.12
Prepaid Expenses	0.32	0.29	-	0.23	0.17	0.34
Total Current Assets	5.09	5.39	5.41	4.99	2.15	4.21
Property, Plant & Equipment	2.9	3.07	3.17	2.46	2.74	2.6
Goodwill	0.3	0.3	0.3	0.3	0.3	0.3
Other Intangible Assets	0.31	0.35	0.38	0.42	0.47	0.52
Total Assets	8.6	9.12	9.26	8.17	5.66	7.63

Liabilities

Fiscal Year	TTM	FY 2025	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	0.18	0.17	0.68	0.14	0.04	0.19
Accrued Expenses	0.27	0.66	-	0.25	0.2	0.15
Current Portion of Long-Term Debt	0.01	0.07	0.23	0.03	0.03	0.02
Current Portion of Leases	0.15	0.16	0.16	0.09	0.08	0.04
Current Unearned Revenue	0.03	-	-	-	0.05	0.04
Other Current Liabilities	0.1	0.1	0.03	0.04	0.01	0.07
Total Current Liabilities	0.86	1.16	1.1	0.55	0.41	0.51
Long-Term Debt	-	-	0.02	0.13	0.17	0.2
Long-Term Leases	0.49	0.56	0.62	0.14	0.2	0.08
Long-Term Unearned Revenue	0.03	-	0.06	-	0.12	0.17
Long-Term Deferred Tax Liabilities	0.19	0.17	0.06	0.07	0.09	0.08
Other Long-Term Liabilities	-	0.04	-	0.09	-	-
Total Liabilities	1.56	1.93	1.86	0.99	0.98	1.04

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	3.1	3.1	3.1	3.1	1.11	1.11
Additional Paid-In Capital	13.71	13.71	13.71	13.71	11.73	11.73
Retained Earnings	-20.4	-20.2	-19.98	-19.99	-18.55	-16.54
Comprehensive Income & Other	10.59	10.54	10.47	10.36	10.39	10.29
Total Common Equity	7	7.14	7.3	7.18	4.68	6.58
Minority Interest	0.04	0.04	0.09	-	-	-
Shareholders' Equity	7.04	7.19	7.39	7.18	4.68	6.58
Total Liabilities & Equity	8.6	9.12	9.26	8.17	5.66	7.63

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	0.65	0.79	1.03	0.39	0.48	0.34
Net Cash (Debt)	1.71	2.46	2.54	3.54	1.01	2.62
Net Cash Growth	-30.21%	-3.23%	-28.35%	251.04%	-61.47%	-55.49%
Net Cash Per Share	0.03	0.04	0.04	0.11	0.05	0.12
Filing Date Shares Outstanding	62.06	62.06	62.06	62.06	22.18	22.18
Total Common Shares Outstanding	62.06	62.06	62.06	62.06	22.18	22.18
Working Capital	4.23	4.23	4.31	4.44	1.74	3.7
Book Value Per Share	0.11	0.12	0.12	0.12	0.21	0.30
Tangible Book Value	6.39	6.5	6.62	6.46	3.91	5.76
Tangible Book Value Per Share	0.10	0.10	0.11	0.10	0.18	0.26
Land	1.99	1.99	-	1.34	1.34	1.34
Machinery	2.77	2.74	-	2.2	2.03	1.72
Construction In Progress	-	-	-	-	0.14	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 25, 2026

Data Sources Report a data error